Genuine monovalent ligands of TrkA nerve growth factor receptors reveal a novel pharmacological mechanism of action

Citation
S. Maliartchouk et al., Genuine monovalent ligands of TrkA nerve growth factor receptors reveal a novel pharmacological mechanism of action, J BIOL CHEM, 275(14), 2000, pp. 9946-9956
Citations number
57
Categorie Soggetti
Biochemistry & Biophysics
Journal title
JOURNAL OF BIOLOGICAL CHEMISTRY
ISSN journal
00219258 → ACNP
Volume
275
Issue
14
Year of publication
2000
Pages
9946 - 9956
Database
ISI
SICI code
0021-9258(20000407)275:14<9946:GMLOTN>2.0.ZU;2-#
Abstract
Developing small molecule agonistic ligands for tyrosine kinase receptors h as been difficult, and it is generally thought that such ligands require bi valency. Moreover, multisubunit receptors are difficult to target, because each subunit contributes to ligand affinity, and each subunit may have dist inct and sometimes opposing functions. Here, the nerve growth factor recept or subunits p75 and the tyrosine kinase TrkA were studied using artificial ligands that bind specifically to their extracellular domain. Bivalent TrkA Ligands afford robust signals. However, genuine monomeric and monovalent T rkA ligands afford partial agonism, activate the tyrosine kinase activity, cause receptor internalization, and induce survival and differentiation in cell lines and primary neurons. Monomeric and monovalent TrkA Ligands can s ynergize with ligands that bind the p75 subunit. However, the p75 ligands u sed in this study must be bivalent, and monovalent p75 ligands have no effe ct. These findings will be useful in designing and developing screens of sm all molecules selective for tyrosine kinase receptors and indicate that str ategies for designing agonists of multisubunit receptors require considerat ion of the role of each subunit. Last, the strategy of using anti-receptor mAbs and small molecule hormone mimics as receptor ligands could be applied to the study of many other heteromeric cell surface receptors.